Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.48 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137660 | 0.91 | P2RX7 (0.50) | P2RX7ALDH1A1HPGDKDM4ETSHR | |
| SCHEMBL4135903 | 0.89 | P2RX7 (0.51) | P2RX7ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL4140408 | 0.88 | P2RX7 (0.59) | P2RX7FSCN1 | |
| SCHEMBL4144738 | 0.88 | P2RX7 (0.51) | P2RX7ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL4155031 | 0.86 | P2RX7 (0.49) | P2RX7ALDH1A1HPGDKDM4ECNR2 | |
| SCHEMBL13774316 | 0.84 | P2RX7 (0.43) | P2RX7FSCN1ALDH1A1HPGDKDM4E | |
| SCHEMBL4132630 | 0.84 | P2RX7 (0.53) | P2RX7ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL4147936 | 0.82 | P2RX7 (0.51) | P2RX7ALDH1A1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4157822 | 0.81 | P2RX7 (0.49) | P2RX7ALDH1A1KDM4ESMN1; SMN2CNR2 | |
| SCHEMBL13243884 | 0.81 | P2RX7 (0.54) | P2RX7ALDH1A1HPGDKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | claimed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | claimed |
| EP-1865774-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2006102588-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885FSCN1 2820/4885ALDH1A1 3640/4885 |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885FSCN1 2820/4885ALDH1A1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.